No study has examined the association between prenatal phthalate exposure and intrauterine growth retardation (IUGR). This study aimed to investigate whether prenatal exposure to phthalates was associated with increased risk of IUGR. Methods: A total of 126 mother-newborn pairs, including 42 IUGR cases and 84 control newborns and their mothers, were enrolled in this case-control study. Spot urine samples were collected during the third trimester of pregnancy, and 5 phthalate metabolites (mono-n-butyl phthalate (MBP), monomethyl phthalate (MMP), mono-2-ethylhexyl phthalate (MEHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), and mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP)) were measured. results: Concentrations of MMP, MEHHP, MEOHP, and SumDEHP (MEHP, MEHHP, and MEOHP) were significantly higher in IUGR cases than in normal controls. In all subjects, urinary concentrations of MEHHP and MEOHP were significantly inversely associated with fetal growth indicators (birth weight and Quetelet's index). When mothers were stratified by infant sex, MEHHP and MEOHP concentrations were still negatively associated with fetal growth indicators, while no significant association was observed in females. In addition, exposureresponse relationships were observed between MEHHP/ SumDEHP concentrations in maternal urine and IUGR. conclusion: Prenatal exposure to phthalates was associated with increased risk of IUGR, and male newborns were more sensitive to phthalates than females.
human burden of phthalates has been reported and the consensus is that phthalate metabolites in urine could be used for assessing phthalate exposure in humans (4) (5) (6) (7) (8) (9) (10) (11) . In most cases, it is the monoester metabolites that have been claimed to be responsible for adverse health effects (12, 13) .
Because phthalates can penetrate the placenta in humans (14) , high phthalate levels in general, and in pregnant women in particular, have raised the urgent issue of prenatal exposure to phthalates. Fetuses are specifically vulnerable to a variety of toxicants because of the immaturity of their developing immune systems and the rapid development of their organs (15, 16) . During the fetal period, there is a "critical window" for the development of cardiovascular, nervous, reproductive, endocrine, immune, and respiratory systems when even a subtle exposure to chemicals may adversely affect morphologies and functions of the systems (17) . Therefore, it is important to examine prenatal phthalate exposure and its effect on fetal health.
Toxicological evidence from animal studies demonstrated that reduced birth weight was one of the most sensitive endpoints for prenatal exposure to phthalates (18, 19) . In female rats exposed to di-n-butyl phthalate (DBP, one phthalate ester), the lowest observed adverse effect level for decreased birth weight in the F 2 generation was 52 mg/kg/d for males and 66 mg/kg/d for females (20) . In human epidemiological studies (21) (22) (23) (24) (25) , statistically significant associations have been observed between prenatal exposure to phthalates and fetal growth indicators (e.g., birth weight, birth length, and gestational age at delivery). These results together indicate that prenatal phthalate exposure may adversely affect fetal growth.
Intrauterine growth restriction (IUGR) is defined as the rate of growth of a fetus that is less than normal for the growth potential of the fetus at particular gestational age (26) . Newborns with IUGR are at increased risk to develop a metabolic syndrome later in life, namely obesity, arterial hypertension, hypercholesterolemia, cardiovascular disease, impaired glucose tolerance, or diabetes mellitus type 2 (27) . Regarding the etiologic factors responsible for IUGR, one-third of the variations in birth weight are determined by genetic variables, while two-thirds are determined by environmental factors (28) . Although previous data showed that prenatal phthalate exposure was associated with reduced fetal growth, no study to date has examined the role of prenatal exposure to phthalates in the development of IUGR. Thus, we conducted this case-control study to investigate whether prenatal phthalate exposure was a risk factor for IUGR. Furthermore, considering gender differences in reproductive and developmental toxicity of phthalates, we also explored the differences in phthalate effect between males and females.
RESULTS

Population Characteristics
The maternal and pregnancy characteristics of IUGR and control patients are listed and compared as shown in Table 1 . Cases and controls differed with regard to birth weight, birth length, Quetelet's index, gestational age at delivery, and passive smoking. Cases and controls did not differ by infant sex, maternal age, prepregnant BMI, pregnancy complications, irregular menstruation, maternal education background, and monthly income. In addition, mothers from both groups had no habit of cigarette smoking or alcohol drinking before and during pregnancy (data not shown).
Urinary Phthalate Metabolites in Pregnant Women
Urinary phthalate metabolites are considered to be good biomarkers for assessing phthalate exposure in humans because of their reliability and low contamination rate in the laboratory (29) . In this study, concentrations of the five phthalate metabolites in urine samples were determined to assess prenatal phthalate exposure.
As shown in Table 2 , phthalate exposure was prevalent. More than 80% of urinary samples had quantifiable levels of the five phthalate metabolites. The lower-molecular-weight phthalate metabolites mono-n-butyl phthalate (MBP) and monomethyl phthalate (MMP) had median values of 21.6 and 8.9 ng/ml, respectively. In comparison, median concentrations of highermolecular-weight phthalate metabolites mono-2-ethylhexyl phthalate (MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono(2-ethyl-5-oxohexyl) phthalate (MEOHP) were 6.5, 10.6, and 4.3 ng/ml, respectively.
Analyses of potential differences in phthalate metabolite concentrations in maternal urine samples between IUGR cases and controls were conducted using the Mann-Whitney U-test. Urinary concentrations of MMP, MEHHP, MEOHP, and SumDEHP were significantly higher in IUGR cases than in normal controls (P=0.030, 0.003, 0.003, and 0.004, respectively). The largest difference in phthalate metabolites was observed in MEOHP, for which the median concentration of cases was 2.2-fold higher than in controls (8.0 ng/ml vs. 3.7 ng/ml, P=0.003) ( Table 2 ).
Association Between Urinary Phthalate Metabolite Concentrations and Birth Outcomes
The relationship between urinary phthalate metabolite concentrations and birth weight is shown in Figure 1 . In all subjects, urinary concentrations of MMP, MEHHP, MEOHP, and SumDEHP were significantly inversely associated with birth weight. After adjusting for the potential confounders (maternal age, gestational age at delivery, maternal education, prepregnancy BMI, and passive smoking), MEHHP and MEOHP remained significant. A log-unit (10-fold) increase in urinary concentrations of MEHHP and MEOHP was associated with 0.213 (β= −0.213; 95% confidence interval (CI), −0.401 to −0.025) and 0.233 (β= −0.233; 95% CI, −0.411 to −0.056) kg decrease in birth weight, respectively. When subjects were stratified by infant gender, MEHHP (β=−0.393; 95% CI, −0.740 to −0.046) and MEOHP (β=−0.434; 95% CI, −0.762 to −0.107) were still found to be inversely associated with birth weight in males even after adjusting for potential confounders. However, no phthalate metabolite was found to be significantly associated with birth weight in females. Figure 2 presents the relationship between urinary phthalate metabolite concentrations and birth length. In the unadjusted Quetelet's index was calculated as weight (in kilograms) divided by the square of height (in meters).
c Prenatal exposure to phthalates and IUGR Articles model, elevated urinary concentrations of MMP, MEHP, MEHHP, MEOHP, and SumDEHP were significantly associated with reduced birth length. Among males, urinary concentrations of higher-molecular-weight phthalate metabolites (MEHP, MEHHP, and SumDEHP) were negatively associated with birth length, while among females, it was the lower-molecular-weight phthalate metabolite (MMP) concentration that was negatively associated with birth length. However, after adjusting for potential confounders, all significances disappeared. Figure 3 presents the regression results for phthalate metabolite levels and Quetelet's index (calculated as weight (in kilograms) divided by the square of height (in meters)). MEHHP and MEOHP concentrations were significantly associated with a decreased Quetelet's index in all subjects in both the crude and adjusted models. A log-unit (10-fold) increase in urinary concentrations of MEHHP and MEOHP was associated with a 0.656 (β=−0.656; 95% CI, −1.307 to −0.005) and 0.816 (β=0.816; 95% CI, −1.426 to −0.206) kg/m 2 decrease in birth weight, respectively. There was an obvious gender difference in the associations between MEHHP/MEOHP concentration and Quetelet's index, which was stronger in males and not statistically significant in females.
Although IUGR newborns seemed to be having shorter gestational age than control newborns (38.17 wk vs. As shown in Figure 4 (30) (31) (32) , which indicated that prenatal phthalate exposure is common. As prenatal phthalate exposure has been shown to be associated with adverse fetal growth, we sought to investigate the association between prenatal exposure to phthalates and IUGR. A single urine sample could be moderately predictive of each subject's exposure over 3 mo (22, 29) . Therefore, urinary phthalate metabolite concentrations during the third trimester of pregnancy could be used for estimating prenatal exposure to phthalates. In this study, the detection rate of phthalate metabolites was over 80%, which indicated that exposure to phthalates was a routine occurrence for the present subjects. The median concentrations of phthalate metabolites ranged from 4.3 to 21.6 ng/ml ( Table 2) . These levels were generally comparable with those reported in urine samples collected from pregnant women in Germany (33), Israel (34), Japan (17), Norway (32), Peru (35), Spain (36), Sweden (6) , and the United States (30) , but the concentrations of DEHP metabolites in our study were somewhat lower.
Our finding that urinary concentrations of phthalate metabolites were negatively associated with fetal growth indicators is consistent with our own previous study (24) . In that study, we determined phthalate levels in umbilical cord blood and fetal meconium, and found that DBP exposure in utero (DBP in Articles cord blood and MBP in meconium) was negatively associated with birth weight, and DEHP exposure (MEHP in cord blood and meconium) was associated with shorter birth length. Especially in this present study, we found a notable difference in effect between males and females. Among males, maternal urinary concentrations of higher-molecular-weight phthalate metabolites (MEHHP and MEOHP) were significantly inversely associated with birth weight and Quetelet's index, while among females no significant association was observed. Our results suggest that male fetuses are more sensitive to prenatal phthalate exposure than females. Previous studies on association between prenatal phthalate exposure and gestational age yielded inconsistent results. Meeker et al. (25) reported that mothers of preterm birth infants had significantly higher urinary MBP and monobenzyl phthalate (MBzP) concentrations during pregnancy than those of full-term infants. In contrast, Wolff et al. (31) found that lower-molecular-weight phthalate metabolites in the urine of pregnant women had a positive association with gestational age. However, we did not find any association between urinary phthalate metabolite concentrations and gestational age, which was consistent with the results of two recent studies (17, 37) . These divergent results might be attributed to diversity between the levels of phthalates measured in different studies.
The most remarkable result in this study is the exposureresponse relationship between urinary phthalate metabolite concentrations and increased IUGR risk. ORs for IUGR were found to be increased with the increasing of MEHHP and SumDEHP exposure levels, and exposure-response relationships were observed between urinary phthalate metabolite concentrations and IUGR risk, especially in the highest tertile (OR up to 5.80). These results indicate that fetuses might be at a higher risk for IUGR after prenatal exposure to phthalates.
There are some limitations in our study. Firstly, our sample size is relatively small. Therefore, statistical power to detect subtle changes might be low. Secondly, phthalate metabolites have short half-lives and our exposure measurements relied on a single urine specimen. Misclassification of exposure and outcome in our study is possible, although they are likely to be independent of one another. Thus, some other biomarkers might be needed to assess prenatal phthalate exposure. Furthermore, the potential confounding from exposure to other pollutants is unclear and cannot be excluded.
In conclusion, the present study provides evidence of potential roles of prenatal phthalate exposure in the development of IUGR among a group of Chinese women. The detection of these associations, even in this small sample size study, may have significant implications due to the widespread distribution of phthalates in the general population. Further studies with a larger sample size, and with more known confounders taken into account, are needed to investigate the causality in these relationships.
METHODS
Study Population
Participants were recruited during their third-trimester examination at the Second Affiliated Hospital of Wenzhou Medical College between March 2012 and January 2013. IUGR was defined as estimated fetal weight (EFW) below the 10th centile for gestational age, based on sonographic measurements of fetal biparietal diameter, head circumference, abdominal circumference, and femur length. For each IUGR fetus, two healthy fetuses were selected as controls matched for maternal age. During the study period, 126 mother-newborn pairs, including 42 IUGR cases and 84 controls and their mothers, were enrolled in our study. All subjects were residents of Wenzhou and signed written informed consents approved by Fudan University's Institutional Review Board. In 2 d after delivery, the mothers answered a detailed questionnaire concerning maternal weight and height before pregnancy, education background, dietary habits, monthly income, and so on. The demographic characteristics of newborns, including birth weight, birth length, and gestational age (calculated by subtracting the date of the last menstrual period from the date of delivery), were obtained from hospital records.
Sample Collection and Measurement
Maternal urine samples were obtained during the third trimester. All specimens were collected with glass devices to avoid contamination by phthalates during handling and storage. Urine samples were stored at −20 °C until analysis. Five phthalate metabolites measured here included two lowermolecular-weight phthalate metabolites (MBP and MMP) and three higher-molecular-weight phthalate metabolites (MEHP, MEOHP, and MEHHP). MBP and MMP are primary metabolites of DBP and dimethyl phthalate (DMP), respectively. MEHP is the primary metabolite of DEHP, and MEHHP and MEOHP are secondary metabolites of DEHP.
Urinary phthalate metabolites were analyzed using a method modified by Guo et al. (38) . Briefly, 0.5 ml of urine sample was enzymatically hydrolyzed and purified by solid-phase extraction. Phthalate metabolites in urine extract were resolved by an Agilent 1100 Series high-performance liquid chromatography (HPLC) system (Agilent Technologies, Santa Clara, CA) and detected by an API 2000 electrospray triple quadrupole mass spectrometer (ESI-MS/MS; Applied Biosystems, Foster City, CA). The limits of detection (LOD) were in the low nanogram per milliliter range for each phthalate metabolite.
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C 4 -labeled internal standards and conjugated internal standards were used to increase the precision of the measurements. One method blank, two quality control samples, and two sets of standards were analyzed along with unknown urine samples. Analysts at the Key Laboratory of Public Health Safety, Ministry of Education were blind to all information concerning our subjects.
Due to the glucuronidation of phthalate metabolites in the liver and their elimination by active tubular secretion, creatinine correction may not be appropriate for urinary phthalate metabolite concentration (29, 39) . Thus, in this study, specific gravity was used to correct for urinary dilution, as recommended by Hauser et al. (29) . Specific gravity was measured using a handheld refractometer (Atago PAL MBP   T3  T1 T2   MMP   T3  T1 T2   MEHP   T3  T1 T2   MEHHP   Tertile of phthalate metabolites   T3  T1 T2   MEOHP   T3  T1 T2   SumDEHP   T3   1   10 Odds ratio (95% Cl) 100 a b
